David L. Cornell, MD

David L. Cornell, MD

David L. Cornell, MD

Assistant Professor
School of Medicine, Omaha Campus


  • Surgical Oncology - Cryosurgery & Immunology
  • Trauma & Surgical Critical Care

Academic Appointments


  • Surgery


  • Assistant Professor

Teaching Activity

  • CORE Surgery Residency Faculty - Creighton SOM Surgical Residency
  • CORE Surgical Educator - Creigthon SOM MS III Clerkship

Publications and Presentations


  • , https://doi.org/10.3389/fonc.2018.00085
  • , 13(9), 907-919
  • , 104, 653-659
  • , 7, 151
  • , 48(2), 214-220
  • , 1(1), 1-2
  • , 48, 214-220
  • , 50, 269-274
  • , 8, 645-652
  • , 60(3), 277-83



Research and Scholarship

Research and Scholarship Interests

  • SIRS, Sepsis, CARS  &  PICS
    Cryosurgery & Immunology
    Traumatic Brain Injury
    Rib plating

Current Research Projects

  • Cryosugery & Immunology:  Analysis of Immune Correlates in Cryosurgery Ablation of Renal Cell Adenocarcinoma".
    GRANT:  LB-595 submitted by David L. Cornell, MD - principal investigatora and with Dr. Patrick Swanson, PhD, Dept of Microbiology and Immunolgoy in collaboration with the Dept of Radiology/IR:  Chad Eicher, MD;  Dept of Urology:  Chairman Michael Feloney, MD, with Lawrence Siref, MD and Joan Delto, MD;  Medical Oncology:  Ralph Hauke, MD.  LOI submitted April 2020, Grant approved August 1st, 2020.  IRB approved January 2020.  Patient enrollment "On-Hold" due to COVID-19 hold by Provost.

    Cryosugery & Immunology:  Neoadjuvant Checkpoint Inhibitors followed by Cryosurgery
    GRANT:  LB-506 submitted by Dr. Patrick Swanson, Principal investigator with David L. Cornell, MD, Co-investigator; in collaboration with the Dept of Radiology Chairman:  Joseph Stavas, MD and Dept of Urology Chairman:  Michale Feloney, MD and Lawrence Siref, MD. LOI submitted December 2018.  Grant submitted March 2019 with IRP protocol #:  1399754.  Unfortunately this grant was denied.

Awards and Honors

  • National Surgical Adjuvant Breast and Bowel Foundation (NSABP): Recipient of the NSABP 2003 “Above & Beyond” award in recognition of ones’ commitment to the Study of Tamoxifen and Raloxifene (STAR Trial) for the prevention of Breast Cancer. Initiated and facilitated the third largest corporate collaboration to date between NSABP and various corporations to educate and increase enrollment in the STAR Trial. , 2003